Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Capital Leases (2021 - 2025)

Aligos Therapeutics' Capital Leases history spans 5 years, with the latest figure at $122000.0 for Q3 2025.

  • For Q3 2025, Capital Leases fell 35.11% year-over-year to $122000.0; the TTM value through Sep 2025 reached $122000.0, down 35.11%, while the annual FY2024 figure was $122000.0, 47.19% down from the prior year.
  • Capital Leases reached $122000.0 in Q3 2025 per ALGS's latest filing, roughly flat from $122000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $261000.0 in Q4 2021 to a low of $53000.0 in Q3 2021.
  • Average Capital Leases over 5 years is $175421.1, with a median of $188000.0 recorded in 2023.
  • Peak YoY movement for Capital Leases: skyrocketed 228.3% in 2022, then plummeted 47.19% in 2024.
  • A 5-year view of Capital Leases shows it stood at $261000.0 in 2021, then dropped by 11.88% to $230000.0 in 2022, then increased by 0.43% to $231000.0 in 2023, then tumbled by 47.19% to $122000.0 in 2024, then changed by 0.0% to $122000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Capital Leases are $122000.0 (Q3 2025), $122000.0 (Q2 2025), and $122000.0 (Q1 2025).